Firm focuses on venom-based paediatric MS treatment
Posted: Tue Jul 21, 2015 6:57 am
Nutra Pharma, a US-based biotechnology company specialising in the acquisition, licensing, and commercialisation of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, has announced it has filed an application with the US Food and Drug Administration (FDA) for orphan drug status for its investigational drug RPI-78M as a treatment for paediatric multiple sclerosis (MS)..... Read More - http://www.ms-uk.org/emergingtherapies